Managing Scientific Risks in Dermatology Trials Webinar

Managing Scientific Risks in Dermatology Trials

Clinical trials in dermatology are not substantially different from those in any other areas of medicine, although they have certain distinguishing features vs other medical specialties. These include development of drugs for topical use (in addition to systemic ones) where the vehicle effect can raise the placebo rates to levels higher than in other specialties. As a result, the need for high-quality clinical data in dermatology trials is essential.

The implementation of advanced statistical monitoring techniques, collectively referred to as scientific surveillance, is essential for identifying data quality risks within centralized monitoring frameworks as traditional monitoring methods may prove insufficient.

Scientific surveillance aims to achieve three primary objectives: 1) detecting inconsistencies in scientific data, 2) predicting risks and 3) identifying inflated placebo responses.

In this webinar, you will gain insights into:

• The specific aspects of scientific surveillance in dermatology clinical trials
• Advanced statistical monitoring techniques that can predict risks, identify inflated placebo responses and manage data quality risks
• The unique challenges of dermatology trials, particularly related to placebo effects in topical treatments and how to safeguard the consistency and reliability of clinical data

Discover how scientific surveillance is transforming data integrity in dermatology trials.

Speakers:

• (Moderator) Dr. Alessandro Maio, MSc, PhD, project oversight sr. director, project delivery – cardiovascular and general medicine (CVGM), PPD clinical research business of Thermo Fisher Scientific
• Rakhi Kilaru, MS, MBA, executive director – statistical science, PPD clinical research business of Thermo Fisher Scientific
• Amy R. Kroeplin, MPH, sr. director – strategic business lead, centralized monitoring, PPD clinical research business of Thermo Fisher Scientific
• Dr. Michael Kuligowski, MD, PhD, MBA, vice president – medical science and strategy, dermatology, PPD clinical research business of Thermo Fisher Scientific